Swiss - Delayed Quote CHF

Sandoz Group AG (SDZ.SW)

31.82

-0.71

(-2.18%)

As of 2:45:06 PM GMT+2. Market Open.

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

All proposals of Board of Directors approved Gilbert Ghostine re-elected as Chairman of Board of Directors; all other Board members standing for re-election confirmed Dividend of CHF 0.60 per registered dividend-paying share approved, representing 24% of core net income Basel, April 15, 2025 – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financial Statements and Consolidated

GlobeNewswire 7 days ago

SDZNY

SDZXF
[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseasesDespite FDA approval nearly a decade ago, etanercept biosimilar continues to be blockedSandoz seeking damages in addition to clearing path for launch Basel, April 14, 20

GlobeNewswire 7 days ago

SDZNY

SDZXF
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling inflammatory diseasesDespite FDA approval nearly a decade ago, etanercept biosimilar continues to be blockedSandoz seeking damages in addition to clearing path for launch Basel, April 14, 2025 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced the filin

GlobeNewswire 8 days ago

SDZNY

SDZXF
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility

MEDIA RELEASENOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and liquidityNew facility replaces initial and unutilized USD 1.25 billion RCF, in place since spin-off in 2023Dual-tranche CHF 400m and single-tranche EUR 500 million bonds issuedProceeds used to fully repay USD 750 million equivalent in USD and EUR term loans and extend debt maturities t

GlobeNewswire 21 days ago

SDZNY

SDZXF
Sandoz reports strong FY 2024 results and Q4 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE FY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in constant currencies (+7% in USD); Q4 net sales of USD 2.7 billion, up by 9% in constant currencies (+7% in USD)Strong sales performances in all three regions, driven by double-digit growth in biosimilars, both in the fourth quarter and full year, benefitting from recent launches and base-business momentumOperating income of USD 307 million, up by 5% in c

GlobeNewswire last month

SDZNY

SDZXF
Stocks to watch this week: Broadcom, Costco, JD.com, Adidas and Greggs

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK last month

APAX.L

LCSHF

LCSHY
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars in USStrengthens US immunology portfolio and increases access to biologics for patients suffering from chronic inflammatory diseases, such as psoriasis and psoriatic arthritisMeeting a variety of patient needs, Pyzchiva® offers full suite of dosing options and extended stability compared with refer

GlobeNewswire last month

SDZNY

SDZXF
Francisco Ballester to retire; Peter Stenico appointed President Region International

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of servicePeter Stenico, currently Global Platform Head Biosimilars and Country President Sandoz Austria, concurrently appointed President Region International and a member of the Sandoz Executive Committee Basel, February 3, 2025 – Sandoz, the global leader in generic and biosimilar medicines, announced today that Francisco B

GlobeNewswire 2 months ago

SDZNY

SDZXF
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

MEDIA RELEASE Strong first year as standalone company; global leader Sandoz uniquely positioned in attractive and growing USD 200 billion market for generics and biosimilarsLeading in home market Europe, which represents half of total sales; strategically positioning company to become #1 in biosimilars in US, with three US launches expected in 2025Ambitious GLP-1 strategy in place, addressing each opportunity with mix of internal capabilities and external partnershipsIndustry-leading pipeline fo

GlobeNewswire 3 months ago

SDZNY

SDZXF
RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement

After Intra-Cellular Therapies (ITCI) announced that it has entered into a settlement agreement with Sandoz (SDZNY) resolving patent litigation related to Intra-Cellular Therapies’ product Caplyta, RBC Capital notes this makes Sandoz the first of the seven ANDA filers to reach a deal. More favorable-than-expected terms for first generic lumateperone settlement bode well for Intra-Cellular’s ability to maintain Caplyta revenue durability, says the firm, which “would be buyers into strength.” RBC

TipRanks 3 months ago

ITCI

SDZNY

SDZXF
Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Strong Buy: Here's What You Should Know

Sandoz Group AG Sponsored ADR (SDZNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 4 months ago

SDZNY

SDZXF
Here's Why Sandoz Group AG Sponsored ADR (SDZNY) Is a Great 'Buy the Bottom' Stock Now

Sandoz Group AG Sponsored ADR (SDZNY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 4 months ago

SDZNY

SDZXF
Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

MEDIA RELEASE Afqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One of several biosimilar value drivers for SandozSandoz remains committed to accelerating patient access by strengthening its biosimilar portfolio, reinforcing global and European leadership Basel, November 15, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the European Commission (EC) has g

GlobeNewswire 5 months ago

SDZNY

SDZXF
Sandoz reports third-quarter and nine-month 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launchesGenerics growth acceleration driven by EuropeThird-quarter net sales¹ of USD 2.6 billion, up 12% in constant currencies (up 11% in USD)Nine-month net sales of USD 7.6 billion, up 9% in constant currencies (up 8% in USD)Net sales growth guidance increased to high-single digit in constant currencies (

GlobeNewswire 5 months ago

SDZNY

SDZXF
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio

MEDIA RELEASE First FDA-approved abbreviated new drug application (ANDA) to reference medicineSingle-dose 100 mg vial for intravenous use, approved for metastatic breast cancerLaunch expected to be near-term growth driver in US market Princeton, NJ, October 11, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has launched a generic paclitaxel formulation in the US, the first generic to its reference medicine to be approved by the US Food and Drug Admi

GlobeNewswire 6 months ago

SDZNY

SDZXF
Introducing Jubbonti® and Wyost®, the first denosumab biosimilars on the Canadian market

— Jubbonti® and Wyost® are first denosumab biosimilars available in Canada, reflecting the Sandoz Purpose of pioneering access for patients — Jubbonti® and Wyost® approved for all indications of respective reference medicines — Sandoz Canada has a leading biosimilars portfolio, with many more in the pipeline BOUCHERVILLE, Quebec, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada, a leader in generics and biosimilars, today announces the launch of two denosumab biosimilars: Jubbonti® and Wyost®. Ju

GlobeNewswire 8 months ago

SDZNY

SDZXF
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Enzeevu™ (aflibercept-abzv) approved to treat neovascular age-related macular degenerationFurther enhances leading US ophthalmology portfolio and increases access for patientsExpected to be key biosimilar growth driver in US Basel, August 12, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has approved Enzeevu™ (aflibe

GlobeNewswire 8 months ago

SDZNY

SDZXF
Sandoz reports second-quarter sales and half-year 2024 results

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong double-digit growth in biosimilars of 29% from existing portfolio and recent launches Second-quarter net sales[1] of USD 2.6 billion, up 9% in constant currencies (up 7% in USD)Half-year net sales of USD 5.0 billion, up 7% in constant currencies (up 6% in USD)Half-year core EBITDA margin[2] of 17.5%, a strong 210 basis point improvement versus H2 2023, driven by favorable biosimilars mix; within H1, mar

GlobeNewswire 8 months ago

SDZNY

SDZXF
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases Launch across Europe, starting today, strengthens well-established Sandoz immunology portfolio in Europe, leveraging existing footprintPyzchiva® first ustekinumab biosimilar to launch in Europe with all reference medicine strengths, including 130mg vial initiation dose for Crohn’s diseasePyzchiva® to treat adults with pl

GlobeNewswire 8 months ago

SDZNY

SDZXF
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US Pyzchiva® (ustekinumab-ttwe) is approved by FDA for all indications of reference medicineFDA granted provisional determination for interchangeability designation for Pyzchiva®Extends Sandoz immunology portfolio and further strengthens biosimilar position Expected to be among first wave of ustekinumab biosimilars to launch in US Basel,

GlobeNewswire 9 months ago

SDZNY

SDZXF

Performance Overview

Return	SDZ.SW	MSCI WORLD (^990100-USD-STRD)
YTD	-12.81%	-8.05%
1-Year	+11.44%	--
3-Year	+7.86%	+15.53%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sandoz Group AG (SDZ.SW)

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility

Sandoz reports strong FY 2024 results and Q4 2024 sales

Stocks to watch this week: Broadcom, Costco, JD.com, Adidas and Greggs

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

Francisco Ballester to retire; Peter Stenico appointed President Region International

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

RBC buyers of Intra-Cellular after ‘more favorable-than-expected’ settlement

Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Strong Buy: Here's What You Should Know

Here's Why Sandoz Group AG Sponsored ADR (SDZNY) Is a Great 'Buy the Bottom' Stock Now

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio

Sandoz reports third-quarter and nine-month 2024 sales

Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio

Introducing Jubbonti® and Wyost®, the first denosumab biosimilars on the Canadian market

Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Sandoz reports second-quarter sales and half-year 2024 results

Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases

FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US

Performance Overview